Merck & Co., Inc. Financial Highlights Package Third Quarter 2022 Table of Contents Table 1: GAAP P&L....................................................................................1 Table 1a: GAAP P&L – Current Year and Prior Year by Quarter.................2 Table 2a: GAAP to Non-GAAP Reconciliation 3Q22 and Sept YTD 22.......3 Table 2b: GAAP to Non-GAAP Reconciliation 3Q21 and Sept YTD 21.......4 Table 3: Sales - Current Year and Prior Year by Quarter...........................5 Table 3a: Sales – U.S. / Ex- U.S. 3Q22........................................................6 Table 3b: Sales – U.S. / Ex- U.S. Sept YTD 22...........................................7 Table 3c: Sales – Pharmaceutical Geographic Split....................................8 Table 4: Other (Income) Expense .............................................................9 -- 1 of 10 -- Sales 14,959 $ 13,154 $ 14% 45,453 $ 35,183 $ 29% Costs, Expenses and Other Cost of sales 3,934 3,450 14% 13,530 9,752 39% Selling, general and administrative 2,520 2,336 8% 7,355 6,804 8% Research and development 4,399 2,445 80% 9,773 9,177 6% Restructuring costs 94 107 -12% 288 487 -41% Other (income) expense, net 429 (450) * 1,576 (1,007) * Income from Continuing Operations Before Taxes 3,583 5,266 -32% 12,931 9,970 30% Income Tax Provision 330 695 1,423 1,436 Net Income from Continuing Operations 3,253 4,571 -29% 11,508 8,534 35% Less: Net Income Attributable to Noncontrolling Interests 5 4 6 9 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 3,248 4,567 -29% 11,502 8,525 35% Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests - - 0% - 766 * Net Income Attributable to Merck & Co., Inc. 3,248 $ 4,567 $ -29% 11,502 $ 9,291 $ 24% Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders: Income from Continuing Operations 1.28 $ 1.81 $ -29% 4.55 $ 3.37 $ 35% Income from Discontinued Operations - - 0% - 0.30 * Net Income 1.28 $ 1.81 $ -29% 4.55 $ 3.67 $ 24% Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: Income from Continuing Operations 1.28 $ 1.80 $ -29% 4.53 $ 3.36 $ 35% Income from Discontinued Operations - - 0% - 0.30 * Net Income 1.28 $ 1.80 $ -29% 4.53 $ 3.66 $ 24% Average Shares Outstanding 2,533 2,530 2,531 2,531 Average Shares Outstanding Assuming Dilution 2,542 2,536 2,540 2,539 Tax Rate from Continuing Operations 9.2% 13.2% 11.0% 14.4% * 100% or greater MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1 GAAP % Change GAAP % Change 3Q22 On June 2, 2021, Merck completed the spin-off of products from its women’s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon & Co. (Organon). The historical results of the businesses that were contributed to Organon in the spin-off are excluded from sales and expenses and reflected as discontinued operations in the company’s Consolidated Statement of Income provided below. 3Q21 Sep YTD 2022 Sep YTD 2021 1 -- 2 of 10 -- Sales 15,901 $ 14,593 $ 14,959 $ 45,453 $ 10,627 $ 11,402 $ 13,154 $ 35,183 $ 13,521 $ 48,704 $ 14% 29% Costs, Expenses and Other Cost of sales 5,380 4,216 3,934 13,530 3,199 3,104 3,450 9,752 3,873 13,626 14% 39% Selling, general and administrative 2,323 2,512 2,520 7,355 2,187 2,281 2,336 6,804 2,830 9,634 8% 8% Research and development 2,576 2,798 4,399 9,773 2,412 4,321 2,445 9,177 3,068 12,245 80% 6% Restructuring costs 53 142 94 288 297 82 107 487 174 661 -12% -41% Other (income) expense, net 708 438 429 1,576 (455) (103) (450) (1,007) (333) (1,341) * * Income from Continuing Operations Before Taxes 4,861 4,487 3,583 12,931 2,987 1,717 5,266 9,970 3,909 13,879 -32% 30% Income Tax Provision 554 538 330 1,423 238 503 695 1,436 85 1,521 Net Income from Continuing Operations 4,307 3,949 3,253 11,508 2,749 1,214 4,571 8,534 3,824 12,358 -29% 35% Less: Net (Loss) Income Attributable to Noncontrolling Interests (3) 5 5 6 4 1 4 9 4 13 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 4,310 3,944 3,248 11,502 2,745 1,213 4,567 8,525 3,820 12,345 -29% 35% Income (Loss) from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests - - - - 434 332 - 766 (62) 704 0% * Net Income Attributable to Merck & Co., Inc. 4,310 $ 3,944 $ 3,248 $ 11,502 $ 3,179 $ 1,545 $ 4,567 $ 9,291 $ 3,758 $ 13,049 $ -29% 24% Basic Earnings (Loss) per Common Share Attributable to Merck & Co., Inc. Common Shareholders: Income from Continuing Operations 1.70 $ 1.56 $ 1.28 $ 4.55 $ 1.08 $ 0.48 $ 1.81 $ 3.37 $ 1.51 $ 4.88 $ -29% 35% Income (Loss) from Discontinued Operations - - - - 0.17 0.13 - 0.30 (0.02) 0.28 0% * Net Income 1.70 $ 1.56 $ 1.28 $ 4.55 $ 1.26 $ 0.61 $ 1.81 $ 3.67 $ 1.49 $ 5.16 $ -29% 24% Earnings (Loss) per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: Income from Continuing Operations 1.70 $ 1.55 $ 1.28 $ 4.53 $ 1.08 $ 0.48 $ 1.80 $ 3.36 $ 1.51 $ 4.86 $ -29% 35% Income (Loss) from Discontinued Operations - - - - 0.17 0.13 - 0.30 (0.02) 0.28 0% * Net Income 1.70 $ 1.55 $ 1.28 $ 4.53 $ 1.25 $ 0.61 $ 1.80 $ 3.66 $ 1.48 $ 5.14 $ -29% 24% Average Shares Outstanding 2,528 2,531 2,533 2,531 2,531 2,533 2,530 2,531 2,527 2,530 Average Shares Outstanding Assuming Dilution 2,537 2,540 2,542 2,540 2,541 2,540 2,536 2,539 2,535 2,538 Tax Rate from Continuing Operations 11.4% 12.0% 9.2% 11.0% 8.0% 29.3% 13.2% 14.4% 2.2% 11.0% * 100% or greater Sum of quarterly amounts may not equal year-to-date amounts due to rounding. % Change 3Q Sep YTD 2022 2Q 3Q Sep YTD 1Q 1Q 2Q 3Q 4Q Full Year 2021 Sep YTD Table 1a MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) 2 -- 3 of 10 -- Third Quarter Cost of sales 3,934 $ 446 54 500 3,434 $ Selling, general and administrative 2,520 22 26 48 2,472 Research and development 4,399 902 1 903 3,496 Restructuring costs 94 94 94 - Other (income) expense, net 429 (26) 350 324 105 Income from Continuing Operations Before Taxes 3,583 (1,344) (175) (350) (1,869) 5,452 Income Tax Provision (Benefit) 330 (302) (3) (35) (3) (77) (3) (414) 744 Net Income from Continuing Operations 3,253 (1,042) (140) (273) (1,455) 4,708 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 3,248 (1,042) (140) (273) (1,455) 4,703 Earnings per Common Share Assuming Dilution from Continuing Operations 1.28 $ (0.40) (0.06) (0.11) (0.57) 1.85 $ Tax Rate 9.2% 13.6% Sep YTD Cost of sales 13,530 $ 1,577 167 1,744 11,786 $ Selling, general and administrative 7,355 137 74 211 7,144 Research and development 9,773 936 30 966 8,807 Restructuring costs 288 288 288 - Other (income) expense, net 1,576 (138) 1,268 1,130 446 Income from Continuing Operations Before Taxes 12,931 (2,512) (559) (1,268) (4,339) 17,270 Income Tax Provision (Benefit) 1,423 (587) (3) (97) (3) (281) (3) (965) 2,388 Net Income from Continuing Operations 11,508 (1,925) (462) (987) (3,374) 14,882 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 11,502 (1,925) (462) (987) (3,374) 14,876 Earnings per Common Share Assuming Dilution from Continuing Operations 4.53 $ (0.76) (0.18) (0.39) (1.33) 5.86 $ Tax Rate 11.0% 13.8% Only the line items that are affected by non-GAAP adjustments are shown. MERCK & CO., INC. THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2022 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2a Non-GAAP Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses for the third quarter and nine month period primarily reflect $887 million of intangible asset impairment charges related to the ArQule, Inc. acquisition and expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, for the third quarter and nine month period primarily reflect royalty income and a decrease in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Adjustment Subtotal 3 -- 4 of 10 -- Third Quarter Cost of sales 3,450 $ 346 48 394 3,056 $ Selling, general and administrative 2,336 61 5 66 2,270 Research and development 2,445 48 8 56 2,389 Restructuring costs 107 107 107 - Other (income) expense, net (450) (10) (684) (694) 244 Income from Continuing Operations Before Taxes 5,266 (445) (168) 684 71 5,195 Income Tax Provision (Benefit) 695 (96) (4) (26) (4) 151 (4) 29 666 Net Income from Continuing Operations 4,571 (349) (142) 533 42 4,529 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 4,567 (349) (142) 533 42 4,525 Earnings per Common Share Assuming Dilution from Continuing Operations 1.80 $ (0.13) (0.06) 0.21 0.02 1.78 $ Tax Rate 13.2% 12.8% Sep YTD Cost of sales 9,752 $ 1,188 113 225 (3) 1,526 8,226 $ Selling, general and administrative 6,804 96 9 105 6,699 Research and development 9,177 82 21 103 9,074 Restructuring costs 487 487 487 - Other (income) expense, net (1,007) 79 (1,503) (1,424) 417 Income from Continuing Operations Before Taxes 9,970 (1,445) (630) 1,503 (225) (797) 10,767 Income Tax Provision (Benefit) 1,436 (283) (4) (82) (4) 331 (4) (257) (4) (291) 1,727 Net Income from Continuing Operations 8,534 (1,162) (548) 1,172 32 (506) 9,040 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 8,525 (1,162) (548) 1,172 32 (506) 9,031 Earnings per Common Share Assuming Dilution from Continuing Operations 3.36 $ (0.46) (0.22) 0.46 0.02 (0.20) 3.56 $ Tax Rate 14.4% 16.0% Only the line items that are affected by non-GAAP adjustments are shown. Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non- GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, for the third quarter and nine month period primarily reflect an increase in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint venture. Additionally, the nine month period also includes a loss on a forward exchange contract entered into in conjunction with the Organon spin-off. Amount included in other (income) expense, net, for the nine month period was partially offset by royalty income related to the prior termination of the Sanofi-Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Represents charges for the discontinuation of COVID-19 development programs. (4) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Certain other items for the nine month period also includes a $207 million net tax benefit related to the settlement of certain federal income tax matters. Adjustment Subtotal Non-GAAP MERCK & CO., INC. THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2021 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) The table below reflects a reconciliation of GAAP to non-GAAP financial information on a continuing operations basis. As Organon results are reflected within discontinued operations, they are excluded from the financial information provided below. GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Certain Other Items Table 2b In 2022, the company changed the treatment of certain items for purposes of its non-GAAP reporting. Historically, Merck’s non-GAAP results excluded expenses for upfront and milestone payments related to collaborations and licensing agreements, as well as charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions, to the extent the charges were considered by the company to be significant to the results of a particular period (as well as any related adjustments recorded in a subsequent period). Beginning in 2022, Merck’s non-GAAP results no longer exclude charges related to these items. Results for 2021 have been recast to conform to the new presentation. 4 -- 5 of 10 -- 1Q 2Q 3Q Sep YTD 1Q 2Q 3Q Sep YTD 4Q Full Year Nom % Ex-Exch % Nom % Ex-Exch % TOTAL SALES (1) $15,901 $14,593 $14,959 $45,453 $10,627 $11,402 $13,154 $35,183 $13,521 $48,704 14 18 29 32 PHARMACEUTICAL 14,107 12,756 12,963 39,826 9,238 9,980 11,496 30,714 12,039 42,754 13 19 30 35 Oncology Keytruda 4,809 5,252 5,426 15,487 3,899 4,176 4,534 12,609 4,577 17,186 20 26 23 28 Alliance Revenue – Lynparza (2) 266 275 284 825 228 248 246 721 268 989 16 23 14 20 Alliance Revenue – Lenvima (2) 227 231 202 660 130 181 188 498 206 704 7 11 33 36 Alliance Revenue – Reblozyl (3) 52 33 39 124 17 17 * * * * Vaccines (4) Gardasil / Gardasil 9 1,460 1,674 2,294 5,428 917 1,234 1,993 4,144 1,528 5,673 15 20 31 35 ProQuad / M-M-R II / Varivax 470 578 668 1,716 449 516 661 1,626 509 2,135 1 3 6 7 RotaTeq 216 173 256 644 158 208 227 593 213 807 12 16 9 11 Pneumovax 23 173 153 131 457 171 152 277 600 292 893 -53 -50 -24 -21 Vaqta 36 35 64 134 34 56 48 138 41 179 33 34 -3 -2 Hospital Acute Care Bridion 395 426 423 1,244 340 387 369 1,096 436 1,532 15 22 13 19 Prevymis 94 103 114 310 82 93 96 270 100 370 19 29 15 22 Dificid 52 66 77 196 27 34 54 115 60 175 42 42 70 70 Primaxin 58 64 63 185 65 60 70 194 65 259 -9 -5 -5 -3 Noxafil 57 60 62 180 67 66 64 197 62 259 -3 5 -9 -3 Invanz 52 46 50 148 57 48 53 157 45 202 -7 -1 -6 -1 Cancidas 53 42 43 138 57 54 56 168 45 212 -24 -19 -18 -15 Zerbaxa 30 46 43 120 (8) (1) (2) (11) 10 (1) * * * * Cardiovascular Alliance Revenue - Adempas/Verquvo (5) 72 98 88 258 74 74 100 248 94 342 -12 -12 4 4 Adempas (6) 61 63 57 181 55 74 59 188 63 252 -5 12 -4 8 Virology Lagevrio 3,247 1,177 436 4,859 952 952 * * * * Isentress / Isentress HD 158 147 161 466 209 192 189 590 178 769 -15 -11 -21 -17 Neuroscience Belsomra 69 69 62 199 79 78 81 238 80 318 -24 -12 -16 -7 Immunology Simponi 186 181 173 540 214 202 203 619 206 825 -15 -2 -13 -2 Remicade 61 53 49 163 85 75 73 233 67 299 -33 -22 -30 -21 Diabetes (7) Januvia 779 756 717 2,252 809 784 852 2,445 878 3,324 -16 -10 -8 -3 Janumet 454 476 417 1,347 486 477 487 1,449 514 1,964 -14 -7 -7 -1 Other Pharmaceutical (8) 520 479 564 1,565 554 512 518 1,589 533 2,118 9 17 -1 3 ANIMAL HEALTH 1,482 1,467 1,371 4,320 1,418 1,472 1,417 4,307 1,261 5,568 -3 4 - 6 Livestock 832 826 829 2,486 819 821 864 2,503 791 3,295 -4 4 -1 6 Companion Animals 650 641 542 1,834 599 651 553 1,804 470 2,273 -2 4 2 6 Other Revenues (9) 312 370 625 1,307 (29) (50) 241 162 221 382 159 41 * * * 200% or greater (6) Net product sales in Merck's marketing territories. (7) Total Diabetes sales were $1,305 million, $1,300 million and $1,231 million in the first, second and third quarter of 2022, respectively, and $1,363 million, $1,330 million, $1,417 million and $1,475 million in the first, second, third and fourth quarter of 2021, respectively. (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $114 million, $32 million and $10 million in the first, second and third quarter of 2022, respectively, and $56 million, $135 million and $27 million in the first, third and fourth quarter of 2021, respectively. Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties and a milestone payment. (4) Total Vaccines sales were $2,481 million, $2,709 million and $3,552 million in the first, second and third quarter of 2022, respectively, and $1,809 million, $2,293 million, $3,315 million and $2,715 million in the first, second, third and fourth quarter of 2021, respectively. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. 2022 2021 3Q September YTD MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3 5 -- 6 of 10 -- 3Q 2022 3Q 2021 % Change 3Q 2022 3Q 2021 % Change 3Q 2022 3Q 2021 % Change TOTAL SALES (1) $14,959 $13,154 14 $7,322 $6,276 17 $7,637 $6,878 11 PHARMACEUTICAL 12,963 11,496 13 6,620 5,670 17 6,343 5,826 9 Oncology Keytruda 5,426 4,534 20 3,331 2,580 29 2,095 1,954 7 Alliance Revenue - Lynparza (2) 284 246 16 144 129 12 140 117 20 Alliance Revenue - Lenvima (2) 202 188 7 142 114 25 60 74 -19 Alliance Revenue - Reblozyl (3) 39 * 32 * 7 * Vaccines (4) Gardasil / Gardasil 9 2,294 1,993 15 957 839 14 1,337 1,154 16 ProQuad / M-M-R II / Varivax 668 661 1 532 537 -1 136 125 9 RotaTeq 256 227 12 154 135 13 102 92 11 Pneumovax 23 131 277 -53 68 181 -62 63 97 -35 Vaqta 64 48 33 27 32 -16 36 16 134 Hospital Acute Care Bridion 423 369 15 233 181 29 190 188 1 Prevymis 114 96 19 49 39 26 64 57 14 Dificid 77 54 42 72 52 37 6 2 146 Primaxin 63 70 -9 -57 63 69 -9 Noxafil 62 64 -3 13 19 -30 49 45 8 Invanz 50 53 -7 2 (2) -174 48 55 -14 Zerbaxa 43 (2) * 24 (1) * 19 (1) * Cancidas 43 56 -24 1 1 81 42 56 -25 Cardiovascular Alliance Revenue - Adempas/Verquvo (5) 88 100 -12 85 73 17 3 27 -90 Adempas (6) 57 59 -5 57 59 -5 Virology Lagevrio 436 * - 436 * Isentress / Isentress HD 161 189 -15 68 77 -12 93 112 -17 Neuroscience Belsomra 62 81 -24 20 23 -13 42 58 -28 Immunology Simponi 173 203 -15 173 203 -15 Remicade 49 73 -33 49 73 -33 Diabetes (7) Januvia 717 852 -16 332 365 -9 385 487 -21 Janumet 417 487 -14 90 86 4 327 401 -18 Other Pharmaceutical (8) 564 518 9 244 210 16 321 306 5 ANIMAL HEALTH 1,371 1,417 -3 475 467 2 896 951 -6 Livestock 829 864 -4 186 190 -2 643 675 -5 Companion Animals 542 553 -2 289 277 4 253 276 -8 Other Revenues (9) 625 241 159 227 139 63 398 101 * * 200% or greater Sum of U.S. plus international may not equal global due to rounding. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $10 million in the third quarter of 2022 and $135 million in the third quarter of 2021. Global U.S. International (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $3,552 million in the third quarter of 2022 and $3,315 million in the third quarter of 2021. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (6) Net product sales in Merck's marketing territories. (7) Total Diabetes sales were $1,231 million in the third quarter of 2022 and $1,417 million in the third quarter of 2021. (8) Includes Pharmaceutical products not individually shown above. Table 3a MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS THIRD QUARTER 2022 (AMOUNTS IN MILLIONS) (UNAUDITED) 6 -- 7 of 10 -- September YTD 2022 September YTD 2021 % Change September YTD 2022 September YTD 2021 % Change September YTD 2022 September YTD 2021 % Change TOTAL SALES (1) $45,453 $35,183 29 $20,927 $16,166 29 $24,526 $19,017 29 PHARMACEUTICAL 39,826 30,714 30 19,119 14,611 31 20,707 16,103 29 Oncology Keytruda 15,487 12,609 23 9,307 7,108 31 6,180 5,501 12 Alliance Revenue - Lynparza (2) 825 721 14 427 371 15 397 350 14 Alliance Revenue - Lenvima (2) 660 498 33 426 287 48 235 211 11 Alliance Revenue - Reblozyl (3) 124 * 87 * 37 * Vaccines (4) Gardasil / Gardasil 9 5,428 4,144 31 1,803 1,605 12 3,624 2,539 43 ProQuad / M-M-R II / Varivax 1,716 1,626 6 1,337 1,255 6 379 371 2 RotaTeq 644 593 9 427 364 17 218 229 -5 Pneumovax 23 457 600 -24 280 354 -21 177 247 -28 Vaqta 134 138 -3 72 80 -9 62 58 6 Hospital Acute Care Bridion 1,244 1,096 13 665 545 22 579 551 5 Prevymis 310 270 15 136 111 23 174 159 9 Dificid 196 115 70 184 108 70 12 7 75 Primaxin 185 194 -5 1 87 185 194 -5 Noxafil 180 197 -9 39 48 -20 141 149 -5 Invanz 148 157 -6 4 (2) * 144 159 -10 Cancidas 138 168 -18 5 4 27 133 164 -19 Zerbaxa 120 (11) * 64 (5) * 55 (6) * Cardiovascular Alliance Revenue - Adempas/Verquvo (5) 258 248 4 244 222 10 14 26 -47 Adempas (6) 181 188 -4 181 188 -4 Virology Lagevrio 4,859 * 1,523 * 3,336 * Isentress / Isentress HD 466 590 -21 196 222 -12 270 368 -27 Neuroscience Belsomra 199 238 -16 60 56 7 139 183 -24 Immunology Simponi 540 619 -13 540 619 -13 Remicade 163 233 -30 163 233 -30 Diabetes (7) Januvia 2,252 2,445 -8 958 997 -4 1,294 1,448 -11 Janumet 1,347 1,449 -7 258 244 6 1,089 1,205 -10 Other Pharmaceutical (8) 1,565 1,589 -1 616 637 -3 949 950 - ANIMAL HEALTH 4,320 4,307 - 1,425 1,363 5 2,894 2,944 -2 Livestock 2,486 2,503 -1 521 508 3 1,965 1,996 -2 Companion Animals 1,834 1,804 2 904 855 6 929 948 -2 Other Revenues (9) 1,307 162 * 383 192 99 925 (30) * * 200% or greater Sum of U.S. plus international may not equal global due to rounding. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $156 million and $191 million on a global basis for September YTD 2022 and 2021, respectively. Global U.S. International (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties and a milestone payment. (4) Total Vaccines sales were $8,743 million and $7,417 million on a global basis for September YTD 2022 and 2021, respectively. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (6) Net product sales in Merck's marketing territories. (7) Total Diabetes sales were $3,836 million and $4,110 million on a global basis for September YTD 2022 and 2021, respectively. (8) Includes Pharmaceutical products not individually shown above. Table 3b MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS SEPTEMBER YEAR-TO-DATE 2022 (AMOUNTS IN MILLIONS) (UNAUDITED) 7 -- 8 of 10 -- TOTAL PHARMACEUTICAL $14,107 $12,756 $12,963 $39,826 $9,238 $9,980 $11,496 $30,714 $12,039 $42,754 13 30 United States 6,773 5,726 6,620 19,119 4,294 4,647 5,670 14,611 5,790 20,401 17 31 % Pharmaceutical Sales 48.0% 44.9% 51.1% 48.0% 46.5% 46.6% 49.3% 47.6% 48.1% 47.7% Europe (1) 3,309 2,677 2,427 8,412 2,276 2,404 2,445 7,124 2,655 9,780 -1 18 % Pharmaceutical Sales 23.5% 21.0% 18.7% 21.1% 24.6% 24.1% 21.3% 23.2% 22.1% 22.9% China 1,113 1,355 1,419 3,887 688 944 1,278 2,910 1,352 4,262 11 34 % Pharmaceutical Sales 7.9% 10.6% 10.9% 9.8% 7.4% 9.5% 11.1% 9.5% 11.2% 10.0% Japan 965 1,092 653 2,710 607 637 614 1,858 771 2,629 6 46 % Pharmaceutical Sales 6.8% 8.6% 5.0% 6.8% 6.6% 6.4% 5.3% 6.0% 6.4% 6.1% Asia Pacific (other than China and Japan) 786 854 702 2,342 437 442 450 1,329 488 1,817 56 76 % Pharmaceutical Sales 5.6% 6.7% 5.4% 5.9% 4.7% 4.4% 3.9% 4.3% 4.1% 4.2% Latin America 435 453 511 1,399 353 379 434 1,166 421 1,587 18 20 % Pharmaceutical Sales 3.1% 3.6% 3.9% 3.5% 3.8% 3.8% 3.8% 3.8% 3.5% 3.7% Eastern Europe/Middle East/Africa 450 339 360 1,149 357 318 362 1,037 278 1,315 -1 11 % Pharmaceutical Sales 3.2% 2.7% 2.8% 2.9% 3.9% 3.2% 3.1% 3.4% 2.3% 3.1% Canada 189 166 166 521 160 157 164 482 167 650 1 8 % Pharmaceutical Sales 1.3% 1.3% 1.3% 1.3% 1.7% 1.6% 1.4% 1.6% 1.4% 1.5% Other 87 94 105 287 66 52 79 197 117 313 33 46 % Pharmaceutical Sales 0.6% 0.6% 0.9% 0.7% 0.8% 0.4% 0.8% 0.6% 0.9% 0.8% 2022 2021 % Change MERCK & CO., INC. PHARMACEUTICAL GEOGRAPHIC SALES - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3c 3Q September YTD 1Q 2Q 3Q Sept YTD 1Q 2Q Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom. 3Q Sept YTD 4Q Full Year 8 -- 9 of 10 -- OTHER (INCOME) EXPENSE, NET 3Q22 3Q21 Sep YTD 2022 Sep YTD 2021 Interest income (40) $ (7) $ (62) $ (27) $ Interest expense 244 196 727 597 Exchange losses 96 46 220 202 Loss (income) from investments in equity securities, net (1) 371 (683) 1,361 (1,535) Net periodic defined benefit plan (credit) cost other than service cost (60) 40 (208) (159) Other, net (182) (42) (462) (85) Total 429 $ (450) $ 1,576 $ (1,007) $ (1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. MERCK & CO., INC. OTHER (INCOME) EXPENSE, NET - GAAP (AMOUNTS IN MILLIONS) (UNAUDITED) Table 4 9 -- 10 of 10 --